Since November 1982 at the Sainte-Justine Hospital in Montreal, ampicillin and cefotaxime were used in association as initial treatment (248 h) for childhood bacterial meningitis. In this report is described the in vitro interaction of the new regimen in comparison with that of the previous ampicillin-chloramphenicol combination against 284 Haemophilus isolates. Among the 156 ampicillin-susceptible, ,3-lactamase-negative isolates, synergy was detected in 13 with ampicillin-cefotaxime, and antagonism was detected in only 1; in contrast, synergy was found in only 2 strains with ampicillin-chloramphenicol, and antagonism was found in 15. These differences were statistically significant (P < 0.01). Such significant differences were not observed among the 128 ampicillin-resistant, ,-lactamase-positive Haemophilus isolates. The synergy of ampiciflincefotaxime did not contribute to a decrease of the MIC of cefotaxime for 90% of isolates tested, whereas the antagonism of ampicillin-chloramphenicol did not contribute to increase the MIC of ampicillin for 90% of isolates tested. (14) noted a bactericidal antagonism between ampicillin and chloramphenicol in 101 of 170 tests performed on 43 Haemophilus isolates. In contrast neither antagonism nor synergism was reported by Ahronheim (1). Feldman (6) found synergy at the inhibitory level in 6 of 13 ampicillinsusceptible and 5 of 8 ampicillin-resistant strains; he did not observe any antagonism but failed to measure the bactericidal interaction. Cole et al. (4) failed also to demonstrate antagonism with eight strains and a short incubation. Mackenzie (12), using eight strains, also found no inhibitory interaction but an antagonism of these antibiotics when they were combined at the bactericidal level. Rocco and Overturf (17) showed that chloramphenicol at or below the MIC prevents the bactericidal activity of ampicillin. More recently, Schauf et al. (18) provided evidence for a one-way antibiotic antagonism; that is, chloramphenicol prevents the bactericidal activity of ampicillin in combinations of the two antibiotics.
The question of synergy or antagonism between ampicillin and chloramphenicol against Haemophilus influenzae remains unresolved. Mathies et al. (13) noted a higher incidence of postmeningitic morbidity and mortality after treatment with ampicillin-chloramphenicol associated with streptomycin for 48 h than with ampicillin alone. Lindberg et al. (11) also found more postmeningitic sequelae in patients who received both ampicillin and chloramphenicol compared with those who received ampicillin alone. Conflicting results of in vitro studies have been published. McBryde et al. (14) noted a bactericidal antagonism between ampicillin and chloramphenicol in 101 of 170 tests performed on 43 Haemophilus isolates. In contrast neither antagonism nor synergism was reported by Ahronheim (1) . Feldman (6) found synergy at the inhibitory level in 6 of 13 ampicillinsusceptible and 5 of 8 ampicillin-resistant strains; he did not observe any antagonism but failed to measure the bactericidal interaction. Cole et al. (4) failed also to demonstrate antagonism with eight strains and a short incubation. Mackenzie (12) , using eight strains, also found no inhibitory interaction but an antagonism of these antibiotics when they were combined at the bactericidal level. Rocco and Overturf (17) showed that chloramphenicol at or below the MIC prevents the bactericidal activity of ampicillin. More recently, Schauf et al. (18) provided evidence for a one-way antibiotic antagonism; that is, chloramphenicol prevents the bactericidal activity of ampicillin in combinations of the two antibiotics.
Since November 1982, at the Sainte-Justine Hospital in Montreal, we have treated childhood bacterial meningitis with an initial (48 h) combination of ampicillin-cefotaxime, thus covering possible ampicillin-resistant H. influenzae with cefotaxime instead of chloramphenicol; a significant reduction of neurological morbidity in culture-proven bacterial meningitis followed the introduction of this new regimen, and the results of this trial have been published (10) . In vitro * Corresponding author. studies in which ampicillin-chloramphenicol treatment was compared with ampicillin-cefotaxime treatment against 284 Haemophilus isolates are reported here.
MATERIALS AND METHODS
Bacterial strains. The strains were isolated between 1980 and 1984 from patients at the Sainte-Justine Hospital. At the time of isolation, they were characterized by satellitic growth on sheep blood agar streaked with a staphylococcal strain; growth on chocolate agar with added C02; and requirements for X, V, or both X and V factors (8) MacFarland standard bacterial suspension was prepared in 2 ml of brain heart infusion broth from a 24 h culture on chocolate agar plates. This suspension was further diluted 1/100 in supplemented brain heart infusion broth; the number of viable bacteria in the diluted suspension was determined after 10-fold dilutions (10-2, 10-3, 10-4) by plating on chocolate agar plates and incubating at 37°C for 24 h with added C02; the 1/100 diluted suspension was inoculated in parallel onto the previously prepared and thawed antibiotic-containing microplates with a repetitive multiple-channel inoculator with eight sterile tips (Seward Laboratory, GIBCO Diagnostic Laboratories, Burlington, Ontario, Canada), which delivered 50 RI per well. The final volume of culture in each well was 100 RI (0.1 ml). The inoculated microplates were incubated at 37°C without CO2 and examined after 24 h; the last dilution of antibiotics alone or of (he combinations showing no visible growth was taken as the MIC.
Determination of the antibiotic interaction. Synergy was defined as a fourfold or greater reduction in the MIC of both antibiotics. Antagonism was defined as a fourfold or greater increase in the MIC of either antibiotic. RESULTS Reproducibility of the micromethod in broth. Six lots of antibiotic-containing microplates were used in this study. Except for the first lot, in which the ampicillin MIC was 1.0 ,ug/ml, the MIC of E. coli ATCC 25922 was equal to or differed by no more than one dilution from the modal or median MICs observed: ampicillin, 4.0 ,ug/ml; chloramphenicol, 2.0 ,ug/ml; cefotaxime, 0.12 Fxg/ml; ampicillinchloramphenicol, 2.0 and 2.0 ,ug/ml, respectively; ampicillincefotaxime, 0.12 and 0.12 ,ug/ml, respectively. The MIC observed with cefotaxime was equal to that reported previously (7) 16 .0 ,ug/ml ( Table 2 ). The MIC90s of cefotaxime and chloramphenicol were similar to those observed with ampicillinsusceptible Haemophilus isolates. Cefotaxime was far more inhibitory than chloramphenicol against the 128 ampicillinresistant Haemophilus isolates (MIC90, 0.03 versus 1.0 ,ugIml, respectively).
Interaction of two antibiotic combinations among 156 ampicillin-susceptible isolates. The number of strains manifesting synergy (Table 3 ) was significantly greater (P < 0.01) with ampicillin-cefotaxime (13 of 156) than with ampicillinchloramphenicol (1 of 156). Antagonism was present with both antibiotic combinations, but it was significantly (P < 595 VOL. 29, 1986 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from between 'ampicillin-chloramphenicol and ampicillincefotaxime in the case of ampicillin-resistant isolates (Table  3) . Synergy was more frequent with ampicillin-cefotaxime (9 strains) than with ampicillin-chloramphenicol (2 strains), but the differences were not statistically significant.
Effect of the two combinations on the activity of each of the three antibiotics among the 284 Haemophilus isolates. Cefotaxime, the most active antibiotic of the ampicillincefotaxime combination, had exactly the same inhibitory activity whether it was used alone or in combination with ampicillin and whether or not the Haemophilus isolate was susceptible to ampicillin ( (16, 19) .
The ampicillin-cefotaxime combination was significantly more frequently synergistic and less frequently antagonistic than the ampicillin-chloramphenicol combination. A possible explanation for the synergistic activity of ampicillin and cefotaxime against susceptible Haemophilus isolates is that they did not compete for the same protein binding sites, with the first acting at site 3 and the second probably at site 1 (16); the potent P-lactamase-inhibiting activity of cefotaxime (15) could result in a similar mechanism of synergy in ampicillinresistant and P-lactamase-producing Haemophilus strains.
The opposite effect of antagonism, however, was also observed with some strains; the possible inducing or selecting effects of ampicillin on 3-lactamase production by a subgroup of ampicillin-resistant Haemophilus isolates could result in antagonism by exposing cefotaxime to very large concentration of inactivating P-lactamase.
The synergistic interaction of ampicillin-cefotaxime and the antagonistic interaction of ampicillin-chloramphenicol could explain, only in part, the results of our previous clinical trial with the same antibiotic combinations in vivo in patients with bacterial meningitis (10) . For example, Kobayashi et al. (9) recently reported a beneficial pharmacokinetic interaction between ampicillin and cefotaxime, the former increasing the peak of the latter in cerebrospinal fluid and delaying the transformation to its less active metabolite. The initial management of bacterial meningitis with synergistic combinations rather than with antagonistic combinations or with one antibiotic alone appears to be a promising avenue toward improvement of the long-term prognosis of H. influenzae meningitis. The clinical superiority of ampicillin-cefotaxime over cefotaxime alone in the initial treatment of childhood bacterial meningitis remains to be proved. However, we encountered in our recent clinical trial (10) a Listeria meningitis; this microorganism is naturally resistant to cefotaxime. Kobayashi et al. (9) initially treated a similar Listeria meningitis infection with cefotaxime alone; the patient died of the infection before appropriate therapy with ampicillin could be instituted.
